245 related articles for article (PubMed ID: 15937082)
1. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.
Zhang X; Miao X; Sun T; Tan W; Qu S; Xiong P; Zhou Y; Lin D
J Med Genet; 2005 Jun; 42(6):479-84. PubMed ID: 15937082
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
Sun T; Miao X; Zhang X; Tan W; Xiong P; Lin D
J Natl Cancer Inst; 2004 Jul; 96(13):1030-6. PubMed ID: 15240787
[TBL] [Abstract][Full Text] [Related]
4. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer].
Yang S; Miao XP; Zhang XM; Sun T; Qu SN; Xiong P; Ye YJ; Guo YL; Tan W; Wang S; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2132-5. PubMed ID: 16313826
[TBL] [Abstract][Full Text] [Related]
5. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
6. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.
Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D
J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185
[TBL] [Abstract][Full Text] [Related]
7. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
8. Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population.
Han W; Zhou Y; Zhong R; Wu C; Song R; Liu L; Zou L; Qiao Y; Zhai K; Chang J; Huang L; Liu L; Lu X; Lou J; Yu D; Tan W; Zhang J; Wang H; Miao X
PLoS One; 2013; 8(8):e71656. PubMed ID: 23951214
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between FAS/FASL gene polymorphisms and susceptibility of coal worker's pneumoconiosis].
Ni CH; Song ZF; Jia XM; Li AP; Li CP; Li SK; Li YM; Wang ZL; Zhou Y; Wang SY; Zhang ZD; Zhou JW
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Sep; 25(9):532-6. PubMed ID: 17997887
[TBL] [Abstract][Full Text] [Related]
10. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
Verim L; Timirci-Kahraman O; Akbulut H; Akbas A; Ozturk T; Turan S; Yaylim I; Ergen A; Ozturk O; Isbir T
In Vivo; 2014; 28(3):397-402. PubMed ID: 24815844
[TBL] [Abstract][Full Text] [Related]
11. FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.
Zhao H; Chen W; Du P; Sun A; Zhuang C; Tong J; Wang L
Tumour Biol; 2015 Jun; 36(6):4319-26. PubMed ID: 25596086
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.
Hsu PI; Lu PJ; Wang EM; Ger LP; Lo GH; Tsay FW; Chen TA; Yang HB; Chen HC; Lin WS; Lai KH
Anticancer Res; 2008; 28(1A):97-103. PubMed ID: 18383830
[TBL] [Abstract][Full Text] [Related]
14. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
15. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma.
Zhang W; Li C; Wang J; He C
Hepatogastroenterology; 2012; 59(113):141-6. PubMed ID: 21940365
[TBL] [Abstract][Full Text] [Related]
16. Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.
Marín LA; Muro M; Moya-Quiles MR; Miras M; Minguela A; Bermejo J; Sanchez-Bueno F; Parrilla P; Alvarez-López MR
Tissue Antigens; 2006 Feb; 67(2):117-26. PubMed ID: 16441482
[TBL] [Abstract][Full Text] [Related]
17. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z
Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma.
Li C; Larson D; Zhang Z; Liu Z; Strom SS; Gershenwald JE; Prieto VG; Lee JE; Ross MI; Mansfield PF; Cormier JN; Duvic M; Grimm EA; Wei Q
Pharmacogenet Genomics; 2006 Apr; 16(4):253-63. PubMed ID: 16538172
[TBL] [Abstract][Full Text] [Related]
19. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
